Genmab — November 2018
-
Tak Bulder...Har svaret.
' -
Yes ..Teller.
-
Early efficacy results with bb21217 CAR T therapy in RRMM at a dose of 150 x 106 CAR+ T cells are encouraging, with 6 of 7 patients demonstrating clinical responses. The adverse events observed to date are consistent with known toxicities of CAR T therapies. https://ash.confex.com/ash/2018/webprogram/Paper116953.html
-
CAR+ T cells were measurable at 6 months post treatment in both evaluable patients. Enrollment in the study is ongoing; longer follow-up and data in more patients will establish whether treatment with bb21217 results in sustained CAR+ T cell persistence and responses. Så duration er stadig uafklaret.
-
Jeg tror, at aktien er på vej i uptrend igen.
-
Beder lige Hans-Henrik Nielsen om en analyse.
-
Skal vi ikke lukke over 950? Jeg er på ingen måde TA ekspert
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind